Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl Hao SunKristen A. CardinalAnthony J. Lee Original Article 18 April 2022 Pages: 737 - 750
Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer Khushboo A. GandhiAmit JoshiVikram Gota Original Article 19 April 2022 Pages: 751 - 759
RETRACTED ARTICLE: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment Mototsugu OyaShuichi KanekoYutaka Okayama Original Article Open access 20 April 2022 Pages: 761 - 772
An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells Oula C. MansourAbraham NudelmanBenny J. Evison Original Article 23 April 2022 Pages: 773 - 784
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients Marit A. C. VermuntMerel van NulandAndries M. Bergman Original Article Open access 25 April 2022 Pages: 785 - 793
Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice Brian F. KieselJoshua J. DeppasJan H. Beumer Original Article 04 May 2022 Pages: 795 - 807
The effects of two gold-N-heterocyclic carbene (NHC) complexes in ovarian cancer cells: a redox proteomic study Lara MassaiLuigi MessoriFrancesca Magherini Original Article Open access 11 May 2022 Pages: 809 - 823
A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma Weiping LiuLingyan PingJun Zhu Clinical Trial Report 23 March 2022 Pages: 825 - 831
Risk factors of proteinuria and potentially protective effect of renin–angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib Hiroaki IkesueKenta YamaokaTohru Hashida Short Communication Open access 07 March 2022 Pages: 833 - 838
Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants Jennifer E. HibmaMelissa O’GormanYazdi K. Pithavala Correction Open access 18 March 2022 Pages: 839 - 839
Editorial Expression of Concern for: Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorigenesis Nidhi NigamJasmine GeorgeYogeshwer Shukla Editorial Expression of Concern 05 April 2022 Pages: 841 - 841
Retraction Note to: MicroRNA‑30c‑regulated HDAC9 mediates chemoresistance of breast cancer Zhongxing LiangAmber FengHyunsuk Shim Retraction Note 24 February 2022 Pages: 843 - 843
